Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Guerbet SA (4G8.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
16.54-0.24 (-1.43%)
At close: 08:04AM CET
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting

    Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, will present data on Elucirem™ (gadopiclenol) injection, Dotarem® (gadoterate meglumine) injection and AI solutions at the 2022 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting.

  • GlobeNewswire

    Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

    Guerbet announces a change in governance for its Artificial Intelligence projects Villepinte, November 3rd, 2022: Guerbet today announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018. Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The ter

  • GlobeNewswire

    Guerbet: Revenue at September 30, 2022

    Revenue on September 30, 2022 Faster growth in Q3 2022 Revenue: +5.1% at CER1 (€187 million)Very dynamic activity in Asia (+18.4%) and within MRI (+17.3%)Cumulative revenue at 9 months: +0.8% at CER (€569.2 million) Update of 2022 financial targets Impact of prioritizing EluciremTM production at the Raleigh plantLike-for-like revenue growth below 2% at CER,2022 EBITDA margin between 13% and 14% (excluding extraordinary costs to optimize the operating structure and change the sales model in China

Advertisement
Advertisement